GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Aurobindo Pharma Ltd (NSE:AUROPHARMA) » Definitions » Cost of Goods Sold

Aurobindo Pharma (NSE:AUROPHARMA) Cost of Goods Sold : ₹126,029 Mil (TTM As of Mar. 2024)


View and export this data going back to 2000. Start your Free Trial

What is Aurobindo Pharma Cost of Goods Sold?

Aurobindo Pharma's cost of goods sold for the three months ended in Mar. 2024 was ₹30,609 Mil. Its cost of goods sold for the trailing twelve months (TTM) ended in Mar. 2024 was ₹126,029 Mil.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Aurobindo Pharma's Gross Margin % for the three months ended in Mar. 2024 was 59.14%.

Cost of Goods Sold is also directly linked to Inventory Turnover. Aurobindo Pharma's Inventory Turnover for the three months ended in Mar. 2024 was 0.62.


Aurobindo Pharma Cost of Goods Sold Historical Data

The historical data trend for Aurobindo Pharma's Cost of Goods Sold can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aurobindo Pharma Cost of Goods Sold Chart

Aurobindo Pharma Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Cost of Goods Sold
Get a 7-Day Free Trial Premium Member Only Premium Member Only 103,124.50 106,110.80 108,151.80 112,932.60 126,029.00

Aurobindo Pharma Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cost of Goods Sold Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 29,309.70 31,547.10 32,367.40 31,505.70 30,608.80

Aurobindo Pharma Cost of Goods Sold Calculation

Cost of Goods Sold is the aggregate cost of goods produced and sold, and services rendered during the reporting period. It excludes Total Operating Expense, such as Depreciation, Depletion and Amortization and Selling, General, & Admin. Expense.

Cost of Goods Sold for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹126,029 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Aurobindo Pharma  (NSE:AUROPHARMA) Cost of Goods Sold Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Aurobindo Pharma's Gross Margin % for the three months ended in Mar. 2024 is calculated as:

Gross Margin %=(Revenue - Cost of Goods Sold) / Revenue
=(74919.2 - 30608.8) / 74919.2
=59.14 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Cost of Goods Sold is also directly linked to another concept called Inventory Turnover:

Aurobindo Pharma's Inventory Turnover for the three months ended in Mar. 2024 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Inventory Turnover measures how fast the company turns over its inventory within a year. A higher inventory turnover means the company has light inventory. Therefore the company spends less money on storage, write downs, and obsolete inventory. If the inventory is too light, it may affect sales because the company may not have enough to meet demand.

Usually retailers pile up their inventories at holiday seasons to meet the stronger demand. Therefore, the inventory of a particular quarter of a year should not be used to calculate inventory turnover. An average inventory is a better indication.


Aurobindo Pharma Cost of Goods Sold Related Terms

Thank you for viewing the detailed overview of Aurobindo Pharma's Cost of Goods Sold provided by GuruFocus.com. Please click on the following links to see related term pages.


Aurobindo Pharma (NSE:AUROPHARMA) Business Description

Traded in Other Exchanges
Address
Plot No. 1, Survey No. 83/1, Galaxy, Floors: 22-24, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad, TG, IND, 500 032
Aurobindo Pharma Ltd is a specialty and generic drug manufacturing company. The company's product portfolio spans a variety of therapeutic areas. The vast majority of the company's sales are generated in the United States, followed by Europe. Most of Aurobindo's sales are derived from its formulations business, with the rest stemming from its active pharmaceutical ingredient operations. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Aurobindo Pharma (NSE:AUROPHARMA) Headlines

No Headlines